Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETRARCA: FLOT vs FLOT plus Herceptin and Pertuzumab in HER2+ Gastric/GEJ Cancer
NCT02581462Phase 3Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jun 2016
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab and pertuzumab in Adenocarcinoma of the stomach (GC) and adenocarcinoma of the gastroesophageal junction, sponsored by Institut für Klinische Krebsforschung. Started Jun 2016; status: completed.
02
Drugs
trastuzumabpertuzumab
03
Conditions
Adenocarcinoma of the stomach (GC)adenocarcinoma of the gastroesophageal junction
Beyond the preview
Go deeper on NCT02581462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581462.